Healthcare / BiotechnologyWarsaw
$2.41
+0.10 (+4.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-8.4M · quality 43.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$103M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-34.0%
↓Gross Margin
-2117.1%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-83.8%
FCF CAGR
—
FCF margin
-428380.1%
FCF / Net income
1.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2100.0 · net income $-5.2M · FCF $-9.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2100.00 | $2100.00 | $2019.00 | $139549.00 | $492492.00 |
| Net Income | $-5.2M | $-5.2M | $-7.9M | $-838592.00 | $-10.0M |
| EBITDA | $-5.2M | $-5.2M | $-7.9M | $-719951.00 | $-10.6M |
| EPS | -0.16 | -0.16 | -0.39 | -0.05 | -0.64 |
| Gross Margin | -2117.1% | -2117.1% | -3913.7% | 31.4% | 62.3% |
| Operating Margin | -246564.3% | -246564.3% | -391377.2% | -562.2% | -2160.9% |
| Net Margin | -246079.2% | -246079.2% | -390778.6% | -600.9% | -2031.6% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 0.02 | 0.04 |
| Current Ratio | 11.43 | 11.43 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.0M | $-9.0M | $-8.4M | $-4.5M | $-6.5M |
| Returns | |||||
| ROE | -34.0% | -34.0% | -176.2% | -11.8% | -129.4% |
| Valuation | |||||
| P/B | 5.10 | 5.10 | 4.26 | 2.91 | 8.51 |
| Growth & Yield | |||||
| Revenue Growth | 4.0% | 4.0% | -98.6% | -71.7% | — |
| EPS Growth | 59.1% | 59.1% | -685.2% | 92.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.39 → -0.16
Residual
-17.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.